Literature DB >> 10577280

Acquired pure megakaryocytic aplasia report of two cases with long-term responses to antithymocyte globulin and cyclosporine.

J W Leach1, K K Hussein, J N George.   

Abstract

Acquired pure megakaryocytic aplasia is a rare disorder defined by severe thrombocytopenia with no other hematologic abnormalities and absent, or severely decreased marrow megakaryocytes. The etiology may be immune suppression of megakaryocyte development. Two patients are described who both responded rapidly to a combination of antithymocyte globulin and cyclosporine and who remain in remission 13-20 months after discontinuation of cyclosporine. This regimen is well described for treatment of aplastic anemia and may also be effective for acquired pure megakaryocytic aplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577280     DOI: 10.1002/(sici)1096-8652(199910)62:2<115::aid-ajh10>3.0.co;2-2

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

2.  Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.

Authors:  Mehrzad Mirzania; Sedigheh Khalili; Akbar Hasanpoor; Ahmad Reza Shamshiri
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

3.  [Acquired amegakaryocytic thrombocytopenia purpura: think of systemic lupus erythematosus].

Authors:  Indretsy Mahavivola Ernestho-ghoud; Odilon Rahamefy; Irina Mamisoa Ranaivo; Malalaniaina Andrianarison; Lala Soavina Ramarozatovo; Fahafahantsoa Rapelanoro Rabenja
Journal:  Pan Afr Med J       Date:  2015-01-29

Review 4.  Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults.

Authors:  Jennifer M-L Tjon; Saskia M C Langemeijer; Constantijn J M Halkes
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.